Werewolf Therapeutics shares double on Ambros merger and $150 million PIPE
NEW YORK, Aug. 21. Werewolf Therapeutics (HOWL) shares more than doubled Friday morning after the company disclosed a definitive merger agreement with privately held Ambros Therapeutics, leaving existing HOWL shareholders with 6.8% of the combined entity. Investors committed $150 million in an oversubscribed PIPE alongside the deal, the company said in a press release.
Key takeaways
- Werewolf Therapeutics (HOWL) shares more than doubled Friday morning after it disclosed a definitive merger with privately held Ambros Therapeutics.
- In the combined company, Ambros holders receive 71.7%, PIPE investors 21.5%, and existing Werewolf shareholders 6.8%.
- Investors committed $150 million in an oversubscribed PIPE alongside the deal.
- The merger gives Werewolf access to neridronate, a late-stage Ambros compound for Complex Regional Pain Syndrome Type 1 (CRPS-1), which has no currently approved treatment.
- Ambros began the CRPS-RISE Phase 3 trial in June, with results expected in 2028.
NEW YORK, Aug. 21. Werewolf Therapeutics (HOWL) shares more than doubled Friday morning after the company disclosed a definitive merger agreement with privately held Ambros Therapeutics, leaving existing HOWL shareholders with 6.8% of the combined entity. Investors committed $150 million in an oversubscribed PIPE alongside the deal, the company said in a press release.
The ownership split is stark. Ambros holders receive 71.7% of the combined company. PIPE investors take 21.5%. Current Werewolf shareholders, who own the public vehicle that makes the transaction possible, land at 6.8%, the release shows.
Neridronate: the asset behind the move
Investors reacted to the merger because it gives Werewolf access to neridronate, a late-stage compound in Ambros's pipeline for Complex Regional Pain Syndrome Type 1, or CRPS-1. The condition affects an estimated 65,000 newly diagnosed U.S. patients each year and has no currently approved treatment, according to the press release. Neridronate has previously received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.
Ambros started the CRPS-RISE Phase 3 clinical trial in June, the company said. Results are expected in 2028. If data support approval, neridronate could become the first FDA-cleared therapy for CRPS-1, the company said. The combined entity expects the PIPE to fund operations through the trial readout and a planned NDA submission.
The shareholder math
Werewolf entered Friday's session with HOWL trading at less than a dollar per share, down more than 10% from its year-to-date high. Wall Street carried a consensus "Moderate Buy" heading into Aug. 21, with a mean price target of about $6, the release shows. At those prices, analysts had viewed the stock as notably undervalued even as a standalone operation.
Friday's surge reversed a large portion of that discount in a single session. For existing shareholders, now holding 6.8% of the combined company, the next major test is neridronate's Phase 3 readout in 2028.